Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s Next? Five Things To Look Out For In October

Coherus To Roll Out Cimerli; Australian Price Rises Kick In

Executive Summary

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

You may also be interested in...



Pfizer Overcomes Attempt To Block Lexiscan ANDA

Injunctive relief has been provided against Hospira’s regadenoson ANDA product only until early October, allowing the US-based generics sponsor to close in on a potential launch.

Coherus Reveals US Launch Plans For Interchangeable Ranibizumab

Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.

Coenen Named As New Medaxes Chief

Medaxes has named Jasmien Coenen as the new managing director of the Belgian off-patent industry association, following the recent passing of former leader Joris Van Assche.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152194

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel